Cryptococcosis epidemiology and demographics: Difference between revisions
Sergekorjian (talk | contribs) No edit summary |
Sergekorjian (talk | contribs) |
||
Line 7: | Line 7: | ||
==Epidemiology and Demographics== | ==Epidemiology and Demographics== | ||
===Prevalence=== | ===Prevalence=== | ||
*The prevalence of cryptococcal antigenemia in the general population is unknown. Given the low incidence, it is thought to be very low. | *The prevalence of cryptococcal antigenemia in the general population is unknown. Given the low incidence in the general population, it is thought to be very low. | ||
*Among HIV patients in the United States, the prevalence of cryptococcal antigenemia is approximately 2.9%, indicating that the prevalence of cryptococcal infection may be high enough to consider targeted screening for HIV patients.<ref name=cdc>C. neoformans Infection Statistics. Centers for Disease Control and Prevention (2015). http://www.cdc.gov/fungal/diseases/cryptococcosis-neoformans/statistics.html Accessed on December 31, 2015</ref> | *Among HIV patients in the United States, the prevalence of cryptococcal antigenemia is approximately 2.9%, indicating that the prevalence of cryptococcal infection may be high enough to consider targeted screening for HIV patients.<ref name=cdc>C. neoformans Infection Statistics. Centers for Disease Control and Prevention (2015). http://www.cdc.gov/fungal/diseases/cryptococcosis-neoformans/statistics.html Accessed on December 31, 2015</ref> | ||
Revision as of 15:52, 31 December 2015
Cryptococcosis Microchapters |
Diagnosis |
---|
Treatment |
Case Studies |
Cryptococcosis epidemiology and demographics On the Web |
American Roentgen Ray Society Images of Cryptococcosis epidemiology and demographics |
Risk calculators and risk factors for Cryptococcosis epidemiology and demographics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Serge Korjian M.D., Yazan Daaboul, M.D.
Overview
The prevalence of cryptococcal antigenemia among patients with HIV in the United States is approximately 2.9%. The overall incidence is estimated to be 0.4 to 1.3 cases per 100,000 population yearly in the United States. Cryptococcosis has no age, gender, or race predilection.[1]
Epidemiology and Demographics
Prevalence
- The prevalence of cryptococcal antigenemia in the general population is unknown. Given the low incidence in the general population, it is thought to be very low.
- Among HIV patients in the United States, the prevalence of cryptococcal antigenemia is approximately 2.9%, indicating that the prevalence of cryptococcal infection may be high enough to consider targeted screening for HIV patients.[1]
Incidence
- Nationally representative estimates for the incidence of cryptococcosis are difficult to establish because cryptococcosis is only reportable in a few states.
- Results from active, population-based surveillance in two US locations in the year 2000 indicated that the annual incidence of cryptococcosis among persons with AIDS was between 2 and 7 cases per 1,000
- The overall incidence is estimated to be 0.4 to 1.3 cases per 100,000 population yearly in the United States.
- C. neoformans is a major cause of illness in people living with HIV/AIDS, with an estimated 1 million cases of cryptococcal meningitis occurring worldwide each year.[1]
Age, Gender, and Race
Cryptococcosis has no age, gender, or race predilection.[1]
References
- ↑ 1.0 1.1 1.2 1.3 C. neoformans Infection Statistics. Centers for Disease Control and Prevention (2015). http://www.cdc.gov/fungal/diseases/cryptococcosis-neoformans/statistics.html Accessed on December 31, 2015